JP2016536012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536012A5 JP2016536012A5 JP2016549206A JP2016549206A JP2016536012A5 JP 2016536012 A5 JP2016536012 A5 JP 2016536012A5 JP 2016549206 A JP2016549206 A JP 2016549206A JP 2016549206 A JP2016549206 A JP 2016549206A JP 2016536012 A5 JP2016536012 A5 JP 2016536012A5
- Authority
- JP
- Japan
- Prior art keywords
- pkal
- inhibitor
- assay
- subject
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361893505P | 2013-10-21 | 2013-10-21 | |
| US61/893,505 | 2013-10-21 | ||
| US201461939837P | 2014-02-14 | 2014-02-14 | |
| US61/939,837 | 2014-02-14 | ||
| PCT/US2014/061247 WO2015061183A1 (en) | 2013-10-21 | 2014-10-17 | Assays for determining plasma kallikrein system biomarkers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144118A Division JP7135039B2 (ja) | 2013-10-21 | 2020-08-28 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016536012A JP2016536012A (ja) | 2016-11-24 |
| JP2016536012A5 true JP2016536012A5 (enExample) | 2017-11-24 |
| JP6757252B2 JP6757252B2 (ja) | 2020-09-16 |
Family
ID=52993413
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549206A Active JP6757252B2 (ja) | 2013-10-21 | 2014-10-17 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2020144118A Active JP7135039B2 (ja) | 2013-10-21 | 2020-08-28 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2022137393A Active JP7668772B2 (ja) | 2013-10-21 | 2022-08-31 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2024117419A Pending JP2024150637A (ja) | 2013-10-21 | 2024-07-23 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144118A Active JP7135039B2 (ja) | 2013-10-21 | 2020-08-28 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2022137393A Active JP7668772B2 (ja) | 2013-10-21 | 2022-08-31 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2024117419A Pending JP2024150637A (ja) | 2013-10-21 | 2024-07-23 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11372002B2 (enExample) |
| EP (2) | EP3808857B1 (enExample) |
| JP (4) | JP6757252B2 (enExample) |
| KR (4) | KR20250066486A (enExample) |
| CN (1) | CN105873951A (enExample) |
| AU (3) | AU2014340450B2 (enExample) |
| BR (1) | BR112016008970B1 (enExample) |
| CA (1) | CA2927824C (enExample) |
| DK (1) | DK3060582T3 (enExample) |
| ES (1) | ES2837858T3 (enExample) |
| IL (3) | IL289514B2 (enExample) |
| PL (1) | PL3060582T3 (enExample) |
| WO (1) | WO2015061183A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2688093T3 (es) | 2010-01-06 | 2018-10-30 | Dyax Corp. | Proteínas de unión a calicreína plasmática |
| IL269565B2 (en) * | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| WO2014113712A1 (en) * | 2013-01-20 | 2014-07-24 | Dyax Corp. | Evaluation and treatment of bradykinin-mediated disorders |
| PL3060908T3 (pl) | 2013-10-21 | 2021-10-25 | Takeda Pharmaceutical Company Limited | Diagnoza i leczenie chorób autoimmunologicznych |
| KR20250066486A (ko) | 2013-10-21 | 2025-05-13 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 |
| KR20240049627A (ko) | 2014-01-21 | 2024-04-16 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도 |
| EP3122782A4 (en) | 2014-03-27 | 2017-09-13 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| IL254292B2 (en) * | 2015-03-30 | 2026-01-01 | Dyax Corp | Plasma kallikrein inhibitors and their uses for preventing the onset of hereditary angioedema |
| IL295914B2 (en) | 2015-08-13 | 2024-09-01 | Takeda Pharmaceuticals Co | Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation |
| CA3002747A1 (en) * | 2015-10-19 | 2017-04-27 | Dyax Corp. | Immunoassay to detect cleaved high molecular weight kininogen |
| IL322971A (en) | 2015-12-15 | 2025-10-01 | Takeda Pharmaceuticals Co | Method for evaluating the efficacy of a drug for a plasma kallikrein-mediated disorder |
| CN109716129B (zh) | 2016-09-16 | 2023-10-03 | 武田药品工业株式会社 | 用于遗传性血管性水肿的rna生物标记 |
| CA3037157A1 (en) * | 2016-09-16 | 2018-03-22 | Dyax Corp. | Metabolite biomarkers for diseases associated with the contact activation system |
| KR102513485B1 (ko) * | 2016-09-16 | 2023-03-23 | 다케다 파머수티컬 컴패니 리미티드 | 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커 |
| EP3521828A1 (en) * | 2018-01-31 | 2019-08-07 | Centogene AG | Method for the diagnosis of hereditary angioedema |
| WO2019165308A1 (en) * | 2018-02-22 | 2019-08-29 | The Regents Of The University Of California | Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema |
| CN111057745B (zh) * | 2019-12-30 | 2022-08-12 | 中国科学院生态环境研究中心 | 一种物质的血液毒性效应的高通量筛选方法 |
| CA3167336A1 (en) | 2020-01-13 | 2021-07-22 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| WO2021202948A2 (en) * | 2020-04-04 | 2021-10-07 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
| CN113777331A (zh) * | 2020-06-09 | 2021-12-10 | 张曼 | 尿液激肽原-1及其多肽片段在烧伤中的应用 |
| CN114166924B (zh) * | 2021-12-03 | 2024-11-22 | 中国医学科学院北京协和医院 | 尿液蛋白标志物在诊断遗传性血管水肿中的用途 |
| EP4548103A2 (en) * | 2022-06-30 | 2025-05-07 | Takeda Pharmaceutical Company Limited | Protein biomarkers for lanadelumab treatment |
| WO2025153806A1 (en) * | 2024-01-15 | 2025-07-24 | Kalvista Pharmaceuticals Limited | Methods for determining amidolytic activity |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1312564C (en) * | 1985-07-12 | 1993-01-12 | Robert W. Colman | Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same |
| US4908431A (en) | 1986-01-22 | 1990-03-13 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human kininogen and methods of preparing same |
| US5047323A (en) | 1986-01-22 | 1991-09-10 | Temple University Of The Commonwealth System Of Higher Education | Method for detecting human kininogen using monoclonal antibodies thereto |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| KR960009766B1 (ko) * | 1986-09-10 | 1996-07-24 | 니혼 소오끼 세이야꾸 가부시기가이샤 | 생리 활성물질 측정법 |
| US4882272A (en) | 1986-10-01 | 1989-11-21 | Temple University - Of The Commonwealth System Of Higher Education | High molecular weight kininogen assay |
| US5025796A (en) | 1988-12-01 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5472945A (en) | 1991-08-13 | 1995-12-05 | Temple University- Of The Commonwealth System Of Higher Education | Modulation of blood pressure and inhibition of platelet activation with kininogen fragment |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| DE69533472T2 (de) | 1994-01-11 | 2006-01-12 | Dyax Corp., Cambridge | Kallikreinhemmende "kunitz-domäne"-proteine und derivaten davon |
| JPH1084995A (ja) | 1996-09-12 | 1998-04-07 | Nippon Zoki Pharmaceut Co Ltd | 血液凝固第ｘｉｉ因子活性化法 |
| US5789261A (en) | 1996-10-30 | 1998-08-04 | Temple University Of The Commonwealth System Of Higher Education | Solid phase immunoassay |
| US6242210B1 (en) * | 1997-05-20 | 2001-06-05 | Actinova Limited | Treatment of bacterial infections |
| JP4346798B2 (ja) | 1999-08-19 | 2009-10-21 | 協和メデックス株式会社 | Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。 |
| US6994852B1 (en) | 1999-11-12 | 2006-02-07 | Temple University-Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
| US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| US7678541B2 (en) * | 2000-11-21 | 2010-03-16 | Hologic, Inc. | Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction |
| JP2002221519A (ja) | 2001-01-29 | 2002-08-09 | Sysmex Corp | 抗凝固剤およびそれを用いた抗凝固剤処理方法 |
| US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
| US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| DK2311432T3 (en) | 2002-06-07 | 2015-02-02 | Dyax Corp | Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure |
| AU2003281287A1 (en) | 2002-07-04 | 2004-01-23 | Oxford Glycosciences (Uk) Ltd | Toxicity markers |
| US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| EP1598428A1 (en) * | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| US8828703B2 (en) | 2005-12-29 | 2014-09-09 | Dyax Corp. | Protease inhibition |
| US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
| JP5322935B2 (ja) | 2006-07-31 | 2013-10-23 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | 血漿カリクレインの阻害薬 |
| WO2008064336A2 (en) | 2006-11-22 | 2008-05-29 | Inivitrogen Corporation | Autoimmune disease biomarkers |
| WO2009026334A2 (en) | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| EP2216651A4 (en) | 2007-10-18 | 2010-12-01 | Miyazaki Prefectural Ind Suppo | BIOMARKERS FOR THE DIAGNOSIS OF LIVER DISEASE |
| AU2008315938B2 (en) | 2007-10-22 | 2014-11-27 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
| WO2010004962A1 (ja) | 2008-07-07 | 2010-01-14 | 日本臓器製薬株式会社 | 線維筋痛症の検査法 |
| WO2010062663A1 (en) | 2008-11-03 | 2010-06-03 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| US20110318359A1 (en) * | 2008-12-02 | 2011-12-29 | Feener Edward P | Method for reducing blood pressure using inhibitors of plasma kallikrein |
| US8637454B2 (en) | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| FR2942233B1 (fr) | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre |
| KR101077275B1 (ko) | 2009-05-07 | 2011-10-27 | 한국기초과학지원연구원 | 당단백질의 당쇄화를 이용한 암 진단 방법 |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| CA2783801A1 (en) | 2009-12-18 | 2011-06-23 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| US9206123B2 (en) | 2009-12-18 | 2015-12-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| ES2688093T3 (es) | 2010-01-06 | 2018-10-30 | Dyax Corp. | Proteínas de unión a calicreína plasmática |
| WO2012009447A2 (en) | 2010-07-13 | 2012-01-19 | University Of Rochester | THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
| JP5937612B2 (ja) | 2010-12-02 | 2016-06-22 | ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ | 血液安定剤を含む採血用デバイス |
| IL269565B2 (en) * | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| US9315811B2 (en) | 2011-06-10 | 2016-04-19 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
| US9187749B2 (en) | 2011-06-10 | 2015-11-17 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| FR2983215B1 (fr) * | 2011-11-28 | 2013-12-20 | Univ Grenoble 1 | Dosage de la capacite de controle de c1inh |
| WO2014113712A1 (en) | 2013-01-20 | 2014-07-24 | Dyax Corp. | Evaluation and treatment of bradykinin-mediated disorders |
| MX2015009914A (es) | 2013-02-01 | 2015-09-25 | Becton Dickinson Co | Dispositivos de recogida de sangre que contienen aditivos de inhibicion de la via de contacto. |
| KR20250066486A (ko) | 2013-10-21 | 2025-05-13 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 |
| PL3060908T3 (pl) | 2013-10-21 | 2021-10-25 | Takeda Pharmaceutical Company Limited | Diagnoza i leczenie chorób autoimmunologicznych |
| KR20240049627A (ko) | 2014-01-21 | 2024-04-16 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도 |
| CA3002747A1 (en) | 2015-10-19 | 2017-04-27 | Dyax Corp. | Immunoassay to detect cleaved high molecular weight kininogen |
| IL322971A (en) | 2015-12-15 | 2025-10-01 | Takeda Pharmaceuticals Co | Method for evaluating the efficacy of a drug for a plasma kallikrein-mediated disorder |
| EP4096687A4 (en) | 2020-01-28 | 2024-02-28 | Orgenesis Inc. | Process and system for acellular therapy |
-
2014
- 2014-10-17 KR KR1020257014548A patent/KR20250066486A/ko active Pending
- 2014-10-17 BR BR112016008970-7A patent/BR112016008970B1/pt active IP Right Grant
- 2014-10-17 EP EP20197583.6A patent/EP3808857B1/en active Active
- 2014-10-17 JP JP2016549206A patent/JP6757252B2/ja active Active
- 2014-10-17 AU AU2014340450A patent/AU2014340450B2/en active Active
- 2014-10-17 CA CA2927824A patent/CA2927824C/en active Active
- 2014-10-17 EP EP14856778.7A patent/EP3060582B1/en active Active
- 2014-10-17 KR KR1020237012295A patent/KR20230054745A/ko not_active Ceased
- 2014-10-17 DK DK14856778.7T patent/DK3060582T3/da active
- 2014-10-17 US US15/030,811 patent/US11372002B2/en active Active
- 2014-10-17 KR KR1020227027698A patent/KR102521947B1/ko active Active
- 2014-10-17 ES ES14856778T patent/ES2837858T3/es active Active
- 2014-10-17 PL PL14856778T patent/PL3060582T3/pl unknown
- 2014-10-17 KR KR1020167013432A patent/KR102432826B1/ko active Active
- 2014-10-17 WO PCT/US2014/061247 patent/WO2015061183A1/en not_active Ceased
- 2014-10-17 IL IL289514A patent/IL289514B2/en unknown
- 2014-10-17 CN CN201480070281.6A patent/CN105873951A/zh active Pending
-
2016
- 2016-04-19 IL IL245205A patent/IL245205B/en active IP Right Grant
-
2020
- 2020-04-19 IL IL274055A patent/IL274055B/en unknown
- 2020-08-10 AU AU2020217316A patent/AU2020217316B2/en active Active
- 2020-08-28 JP JP2020144118A patent/JP7135039B2/ja active Active
-
2021
- 2021-12-20 US US17/555,636 patent/US12442824B2/en active Active
-
2022
- 2022-08-31 JP JP2022137393A patent/JP7668772B2/ja active Active
-
2024
- 2024-05-21 AU AU2024203355A patent/AU2024203355A1/en active Pending
- 2024-07-23 JP JP2024117419A patent/JP2024150637A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Single-cell transcriptomic atlas of primate cardiopulmonary aging | |
| Huang et al. | Urinary Xist is a potential biomarker for membranous nephropathy | |
| Liao et al. | Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma | |
| CY1122871T1 (el) | Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1 | |
| Ye et al. | The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma | |
| JP2016511823A5 (enExample) | ||
| Li et al. | MiR-217 is involved in the carcinogenesis of gastric cancer by down-regulating CDH1 expression | |
| MX2020001156A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| JP2017500584A5 (enExample) | ||
| Wang et al. | Circulating exosomes and exosomal lncRNA HIF1A-AS1 in atherosclerosis | |
| Kovalenko et al. | ROS production, intracellular HSP70 levels and their relationship in human neutrophils: effects of age | |
| JP2012500389A5 (enExample) | ||
| JP2008537474A5 (enExample) | ||
| JP2015523569A5 (enExample) | ||
| CN106544342B (zh) | Mt2a基因组蛋白乙酰化修饰检测试剂盒及引物对 | |
| US20190383809A1 (en) | A Novel Autophagy-Related Nourin Gene-Based RNA Network as Early Biomarkers for Cardiac Patients | |
| JP2024075761A (ja) | 脳卒中の血液バイオマーカー | |
| Ramsay et al. | Blood transcriptomic biomarker as a surrogate of ischemic brain gene expression | |
| Menteşe et al. | The diagnostic and prognostic significance of SCUBE1 levels in Crimean-Congo hemorrhagic fever | |
| Srivastava et al. | Development of a novel cell-based assay to diagnose recurrent focal segmental glomerulosclerosis patients | |
| Hermanns et al. | LPS-induced effects on angiotensin I-converting enzyme expression and shedding in human pulmonary microvascular endothelial cells | |
| MX2021009281A (es) | Metodos de deteccion de legionella. | |
| Shen et al. | Screening of differentially expressed genes related to severe sepsis induced by multiple trauma with DNA microarray. | |
| WO2015121737A4 (en) | Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure | |
| JP2016521543A (ja) | Ｈｄａｃ阻害剤治療を必要とする可能性がある患者における診断および予後用途のための遺伝子発現バイオマーカーおよびそれらの使用 |